Home › Trials › NCT06779773

Observational study on the use of Avacincaptad Pegol in patients with geographic atrophy

A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Astellas Pharma Inc · NCT06779773

This study looks at how well Avacincaptad pegol works and its safety for people with geographic atrophy from age-related macular degeneration by reviewing their medical records and collecting their feedback.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
SexAll
SponsorAstellas Pharma Inc (industry)
Locations65 sites (Phoenix, Arizona and 64 other locations)
Trial IDNCT06779773 on ClinicalTrials.gov

What this trial studies

This observational study focuses on individuals with geographic atrophy due to age-related macular degeneration (AMD). It aims to gather data on the treatment patterns and safety of Avacincaptad pegol, an approved therapy for this condition, by reviewing medical records of patients receiving this treatment in routine clinical practice. Participants will have geographic atrophy in one or both eyes and will be monitored for any medical issues related to the treatment. The study will also collect patient-reported outcomes to assess functional impacts.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with geographic atrophy secondary to AMD who are willing to receive treatment with Avacincaptad pegol.

Not a fit: Patients with contraindications to Avacincaptad pegol or those currently participating in other investigational programs may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness and safety of Avacincaptad pegol for patients with geographic atrophy.

How similar studies have performed: While this study is observational, similar studies evaluating treatment patterns for geographic atrophy have shown promising results, indicating the potential for meaningful insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
* Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
* Patient willingness to complete the patient reported outcome (PRO).

Exclusion Criteria:

* Patients who have any contraindication or are not eligible for treatment with ACP, including the following:

  * Active ocular or peri-ocular infection in either eye
  * Active, suspected intraocular inflammation in either eye at enrollment/baseline visit
  * Hypersensitive to ACP or to any ingredient in the formulation
* Patients currently participating in an investigational program with interventions outside of routine clinical practice.
* Patients who have received ACP in the study eye. Note: Patients who have received or are receiving ACP in the fellow eye are eligible to be included in the study.
* Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.

Where this trial is running

Phoenix, Arizona and 64 other locations

+15 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Geographic Atrophy, Macular Degeneration, Avacincaptad Pegol, IZERVAY™, Treatment patterns, Safety, Functional Outcomes

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.